Literature DB >> 22274882

Objective response to sorafenib in advanced clear-cell sarcoma.

O Mir1, P Boudou-Rouquette2, F Larousserie2, A Babinet2, V Dumaine2, P Anract2, F Goldwasser2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22274882     DOI： 10.1093/annonc/mds005

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

1.  Molecular Characteristics of Genes and the Immune Microenvironment of a Rare Chest Malignant Tumor (Pulmonary Clear Cell Sarcoma): A Case Report.

Authors:  Xiaoling Xu; Ding Wang; Wei Wu; Hongyang Lu
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

2.  Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report.

Authors:  Marcella Tazzari; Elena Palassini; Barbara Vergani; Antonello Villa; Francesca Rini; Tiziana Negri; Chiara Colombo; Flavio Crippa; Carlo Morosi; Paolo G Casali; Silvana Pilotti; Silvia Stacchiotti; Licia Rivoltini; Chiara Castelli
Journal:  BMC Cancer       Date:  2015-02-14       Impact factor: 4.430

3.  Clear cell sarcoma of the esophagus: A rare location.

Authors:  Yosra Yahyaoui; Yosr Zenzri; Khalil Behi; Nadia Boujelbene; Amina Mokrani; Imen Abbas; Karima Mrad; Amel Mezlini
Journal:  Clin Case Rep       Date:  2019-12-22

4.  Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS).

Authors:  Xavier Garcia del Muro; Enrique de Alava; Vicenç Artigas; Silvia Bague; Alejandro Braña; Ricardo Cubedo; Josefina Cruz; Nuria Mulet-Margalef; Jose A Narvaez; Oscar Martinez Tirado; Claudia Valverde; Ramona Verges; Joan Viñals; Javier Martin-Broto
Journal:  Cancer Chemother Pharmacol       Date:  2015-11-12       Impact factor: 3.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.